Antimykotika: Indikationen in der klinischen Praxis

• Literatur

• 1 Gullo A. Invasive fungal infections: the challenge continues. Drugs 2009; 69 : 65-73
• 2 Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45: 321-346
• 3 Azoulay E, Dupont H, Tabah A et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 2012; 40: 813-822
• 4 Report ES. European Center for Disease and Prevention Control. Point prevalence survey of health-care associated infections and antimicrobial use in European acute care hospitals. Stockholm: 2013
• 5 Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317
• 6 Kett DH, Azoulay E, Echeverria PM et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39: 665-670
• 7 Zarb P, Coignard B, Griskeviciene J et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2012; 17
• 8 Leon C, Alvarez-Lerma F, Ruiz-Santana S et al. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur J Clin Microbiol Infect Dis 2009; 28: 233-242
• 9 Meersseman W, Vandecasteele SJ, Wilmer A et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-625
• 10 Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-785
• 11 Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-758
• 12 Playford EG, Lipman J, Kabir M et al. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 2009; 35: 2141-2145
• 13 Solomkin JS. Timing of treatment for nonneutropenic patients colonized with Candida. Am J Surg 1996; 172: 44S-48S
• 14 Piarroux R, Grenouillet F, Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-2449
• 15 Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system („Candida score“) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-737
• 16 Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the „Candida score“ for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-1633
• 17 Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-276
• 18 Groll AH, Buchheidt D, Cornely O et al. Diagnose und Therapie von Candida-Infektionen. Chemoth J 2011; 20: 67-93
• 19 Cuenca-Estrella M, Verweij PE, Arendrup MC et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 (Suppl. 07) 9-18
• 20 Affolter K, Tamm M, Jahn K et al. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med 2014; 190: 309-317
• 21 Acosta J, Catalan M, del Palacio-Perez-Medel A et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1--> 3)-beta-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect 2011; 17: 1053-1060
• 22 Hummel M, Spiess B, Cornely OA et al. Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur J Hematol 2010; 85: 164-169
• 23 Reinwald M, Konietzka CA, Kolve H et al. Assessment of Aspergillus-specific PCR as a screening method for invasive aspergillosis in paediatric cancer patients and allogeneic haematopoietic stem cell recipients with suspected infections. Mycoses 2014; 57: 537-543
• 24 Marchetti O, Lamoth F, Mikulska M et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-854
• 25 Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS –100 years after the discovery of Cryptococcus neoformans. Clinical Microbiol Rev 1995; 8: 515-548
• 26 Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31
• 27 Hsu DI, Nguyen M, Nguyen L et al. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010; 65: 1765-1770
• 28 Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645
• 29 Labelle AJ, Micek ST, Roubinian N et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-2972
• 30 Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infectious disease clinics of North America 2006; 20: 545-561
• 31 Berenguer J, Buck M, Witebsky F et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: 103-109
• 32 Ellepola AN, Morrison CJ. Laboratory diagnosis of invasive candidiasis. J Microbiol 2005; 43: 65-84
• 33 Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med 2012; 125: 14-24
• 34 Ullmann AJ, Akova M, Herbrecht R et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18 : 53-67
• 35 Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535
• 36 Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-1072
• 37 Garbino J, Lew DP, Romand JA et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717
• 38 Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-548
• 39 Playford EG, Webster AC, Sorrell TC et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57: 628-638
• 40 Shorr AF, Chung K, Jackson WL et al. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33: 1928-1935 (quiz 1936)
• 41 Cornely OA, Bassetti M, Calandra T et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18: 19-37
• 42 Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2010; .pub3: CD003940
• 43 Anthony NG, Breen D, Clarke J et al. Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups. J Med Chem 2007; 50: 6116-6125
• 44 Garey KW, Neuhauser MM, Bearden DT et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006; 49: 226-231
• 45 Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248
• 46 Taur Y, Cohen N, Dubnow S et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-190
• 47 Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 3871-3874
• 48 Digby J, Kalbfleisch J, Glenn A et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10: 882-885
• 49 Koo S, Bryar JM, Page JH et al. Diagnostic performance of the 1,3-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650-1659
• 50 Mohr JF, Sims C, Paetznick V et al. Prospective survey of 1,3-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49: 58-61
• 51 Pickering JW, Sant HW, Bowles CA et al. Evaluation of a 1,3-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-5962
• 52 Presterl E, Parschalk B, Bauer E et al. Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009; 13: 707-712
• 53 Takesue Y, Kakehashi M, Ohge H et al. Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004; 28: 625-630
• 54 Meersseman W, Lagrou K, Spriet I et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective autopsy study. Intensive Care Med 2009; 35: 1526-1531
• 55 Maschmeyer G. Onkopedia Leitlinien: Infektionen bei hämatologischen und onkologischen Patienten. 2014 www.dgho-onkopedia.de
• 56 Maschmeyer G, Carratala J, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 2015; 26: 21-33
• 57 Liss B, Vehreschild JJ, Bangard C et al. Our 2015 approach to invasive pulmonary aspergillosis. Mycoses 2015; 58: 375-382
• 58 Luzzati R, Amalfitano G, Lazzarini L et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19: 602-607
• 59 Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-186
• 60 Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21: 994-996
• 61 Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41 : 389-393
• 62 Anaissie EJ, Rex JH, Uzun O et al. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-245
• 63 Nguyen MH, Peacock Jr JE, Tanner DC et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-2435
• 64 Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 2001; 33: 1959-1967
• 65 Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109
• 66 Edwards Jr JE, Bodey GP, Bowden RA et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997; 25: 43-59
• 67 Groll AH, Shah PM, Mentzel C et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32
• 68 Kume H, Yamazaki T, Abe M et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003; 53: 744-750
• 69 Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684
• 70 Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527
• 71 Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029
• 72 Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893
• 73 Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482
• 74 Perez-Parra A, Munoz P, Guinea J et al. Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals?. Intensive Care Med 2009; 35: 707-712
• 75 Kauffman CA. Diagnosis and management of fungal urinary tract infection. Infectious disease clinics of North America 2014; 28: 61-74
• 76 Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010; 23: 253-273
• 77 Hermsen ED, Zapapas MK, Maiefski M et al. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care 2011; 15: R198
• 78 Leroy G, Lambiotte F, Thevenin D et al. Evaluation of „Candida score“ in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care 2011; 1: 50
• 79 Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54: 46-51
• 80 Mousset S, Böhme A, Buchheidt D et al. Onkopedia Leitlinien: Invasive Pilzinfektionen Therapie. 2014 www.dgho-onkopedia.de
• 81 Mousset S, Buchheidt D, Heinz W et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93: 13-32
• 82 Marr KA, Schlamm HT, Herbrecht R et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Internal Med 2015; 162: 81-89
• 83 Ashbee HR, Barnes RA, Johnson EM et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antibicrob Chemother 2014; 69: 1162-1176
• 84 Chau MM, Kong DC, van Hal SJ et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Internal Med J 2014; 44: 1364-1388
• 85 Park WB, Kim NH, Kim KH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080-1087
• 86 van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 2009; 35: 283-309
• 87 de Repentigny L, Phaneuf M, Mathieu LG. Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun 1992; 60: 4907-4914
• 88 Chai LY, Denning DW, Warn P. Candida tropicalis in human disease. Crit Rev Microbiol 2010; 36: 282-298
• 89 Finkelstein R, Reinhertz G, Hashman N et al. Outbreak of Candida tropicalis fungemia in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1993; 14: 587-590
• 90 Hernandez-Castro R, Arroyo-Escalante S, Carrillo-Casas EM et al. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr 2010; 169: 783-787
• 91 Huang YC, Lin TY, Peng HL et al. Outbreak of Candida albicans fungaemia in a neonatal intensive care unit. Scand J Infect Dis 1998; 30: 137-142
• 92 Roilides E, Farmaki E, Evdoridou J et al. Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol 2003; 41: 735-741
• 93 Asmundsdottir LR, Erlendsdottir H, Haraldsson G et al. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008; 47: e17-e24